Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Payables: 2009-2025

Historic Payables for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Sep 2025 value amounting to $468.0 million.

  • UNITED THERAPEUTICS's Payables rose 28.61% to $468.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 24.70%. This contributed to the annual value of $344.5 million for FY2024, which is 15.60% up from last year.
  • According to the latest figures from Q3 2025, UNITED THERAPEUTICS's Payables is $468.0 million, which was up 8.33% from $432.0 million recorded in Q2 2025.
  • In the past 5 years, UNITED THERAPEUTICS's Payables ranged from a high of $468.0 million in Q3 2025 and a low of $165.0 million during Q1 2021.
  • Over the past 3 years, UNITED THERAPEUTICS's median Payables value was $333.4 million (recorded in 2023), while the average stood at $342.6 million.
  • Its Payables has fluctuated over the past 5 years, first decreased by 6.63% in 2021, then spiked by 51.48% in 2023.
  • Quarterly analysis of 5 years shows UNITED THERAPEUTICS's Payables stood at $174.6 million in 2021, then surged by 31.67% to $229.9 million in 2022, then increased by 29.62% to $298.0 million in 2023, then rose by 15.60% to $344.5 million in 2024, then rose by 28.61% to $468.0 million in 2025.
  • Its Payables stands at $468.0 million for Q3 2025, versus $432.0 million for Q2 2025 and $367.0 million for Q1 2025.